Earlier roles on record: CFO at TherapeuticsMD, Inc. (TXMD) until January 11, 2023 and Chief Accounting Officer at TherapeuticsMD, Inc. (TXMD) until December 30, 2022. TherapeuticsMD, Inc. reported in an 8-K filed January 18, 2023 that Michael Donegan was terminated as Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance, effective December 30, 2022. The proxy statement of TherapeuticsMD, Inc. reports total compensation of $1,286,663 for Michael Donegan in fiscal 2023, including a base salary of $532,086. Disclosed compensation is on record for 5 fiscal years. Michael Donegan has spoken on 1 earnings call across 1 company, most recently for TherapeuticsMD, Inc. on August 15, 2022. The companies whose calls Michael Donegan spoke on are classified in the Healthcare sector.
“On January 11, 2023, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company's Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance (the "Employment Agreement"). The termination, effective as of December 30, 2022, is a termination without "Good Cause," as defined in the Employment Agreement.”
TherapeuticsMD, Inc. Form 8-K, filed January 18, 2023
· Read the filing
Michael Donegan on recent calls
“On April 14, we completed the divestiture of vitaCare Prescription Services for $142.6 million net of transaction costs and recognized a gain of $143.4 million on the sale.”
